$CAMP SEC Filings

Filed On	Filing
28 Sep 2026	8-K: Regulation FD Disclosure; Other Events On September 28, 2026, CAMP4 Therapeutics Corporation (the “Company”) held an Analyst Day meeting regarding its planned Phase 1/2 ASCEND clinical trial of CMP-002 in SYNGAP1-related disorder (the “ASCEND clinical trial”) and its pipeline...
02 Sep 2026	Form 4: Gold Kelly, Chief Financial Officer Bought 10,000 shares ($39.6K)
31 Aug 2026	SCHEDULE 13D/A
31 Aug 2026	Form 4: Schwab Andrew J., Director Sold 400,000 shares ($1.62M)
26 Aug 2026	Form 4: Schwab Andrew J., Director Sold 10 shares ($45)
21 Aug 2026	Form 4: Schwab Andrew J., Director Sold 45,147 shares ($215K) · Sold 114,700 shares ($521K) · Sold 32,018 shares ($144K)
19 Aug 2026	Form 4: Tardiff Daniel, Chief Scientific Officer Sold 1,738 shares ($8.27K)
19 Aug 2026	SCHEDULE 13D/A
19 Aug 2026	144
14 Aug 2026	SCHEDULE 13G/A
13 Aug 2026	10-Q
13 Aug 2026	8-K: Results of Operations and Financial Condition
12 Aug 2026	EFFECT
12 Aug 2026	424B3
10 Aug 2026	SCHEDULE 13G
06 Aug 2026	S-3
05 Aug 2026	SCHEDULE 13D/A
05 Aug 2026	Form 4: 5AM Partners VI, Llc, 10% owner and 6 others Acquired 3,179,558 Pre-Funded Warrant (Right to Buy) (Open Market Purchase) ($4.86M)
05 Aug 2026	Form 4: Schwab Andrew J., Director Granted 3,179,558 Pre-Funded Warrant (Right to Buy) ($4.86M)
05 Aug 2026	Form 4: Young Richard A, Director Bought 16,378 shares ($27K)

Comments